Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-02 01:04 | 2025-09-29 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Director | SELL | $30.08 | 78,693 | $2,367,471 | 794,075 |
| 2025-10-01 23:55 | 2025-09-30 | IONS | IONIS PHARMACEUTICALS INC | Geary Richard S | Officer | OPT+S | $65.24 | 57,900 | $3,777,668 | 79,657 |
| 2025-10-02 00:46 | 2025-09-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $14.01 | 1,300 | $18,213 | 202,633 |
| 2025-10-02 00:47 | 2025-09-29 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $13.99 | 1,800 | $25,183 | 17,133 |
| 2025-10-01 23:20 | 2025-09-30 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $48.25 | 8,588 | $414,371 | 1,147,258 |
| 2025-10-01 23:00 | 2025-09-30 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $29.00 | 8,240 | $238,960 | 9,088 |
| 2025-10-02 00:16 | 2025-09-29 | PGEN | PRECIGEN, INC. | KINDLER JEFFREY B | Director | SELL | $3.47 | 174,360 | $604,192 | 346,070 |
| 2025-10-01 23:31 | 2025-09-29 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $421.80 | 22,500 | $9,490,511 | 0 |
| 2025-10-01 15:00 | 2025-09-29 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $424.24 | 8,000 | $3,393,884 | 130 |
| 2025-10-01 23:55 | 2025-09-30 | IONS | IONIS PHARMACEUTICALS INC | HOUGEN ELIZABETH L | Officer | OPT+S | $65.26 | 49,800 | $3,249,734 | 110,500 |
| 2025-10-01 23:10 | 2025-09-30 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.38 | 20,664 | $834,412 | 40,674 |
| 2025-10-01 23:26 | 2025-10-01 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $55.05 | 5,000 | $275,250 | 368,108 |
| 2025-10-01 23:24 | 2025-10-01 | RMTI | ROCKWELL MEDICAL, INC. | Chole Timothy | Officer | SELL | $1.19 | 2,868 | $3,413 | 125,299 |
| 2025-10-01 23:23 | 2025-10-01 | RMTI | ROCKWELL MEDICAL, INC. | Neri Jesse | Officer | SELL | $1.19 | 886 | $1,054 | 125,728 |
| 2025-10-01 23:22 | 2025-10-01 | RMTI | ROCKWELL MEDICAL, INC. | Strobeck Mark | Director, Officer | SELL | $1.19 | 6,926 | $8,242 | 330,826 |
| 2025-09-30 16:00 | 2025-09-29 | IMRX | Immuneering Corp | Feinberg Peter | Director | BUY | $7.18 | 5,000 | $35,900 | 141,766 |
| 2025-10-01 01:59 | 2025-09-29 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Officer | SELL | $13.00 | 2,831 | $36,803 | 27,363 |
| 2025-09-30 23:09 | 2025-09-26 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Director, Officer | OPT+S | $29.11 | 25,000 | $727,798 | 547,343 |
| 2025-10-01 00:51 | 2025-09-26 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.06 | 3,700 | $74,228 | 915,392 |
| 2025-10-01 00:53 | 2025-09-26 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $20.25 | 4,000 | $81,005 | 927,688 |
| 2025-09-30 23:42 | 2025-09-26 | CRNX | Crinetics Pharmaceuticals, Inc. | Struthers Richard Scott | Director, Officer | SELL | $45.00 | 4,000 | $180,000 | 106,000 |
| 2025-10-01 00:56 | 2025-09-26 | AGIO | Agios Pharmaceuticals Inc. | Jones Cecilia | Officer | OPT+S | $36.77 | 3,651 | $134,247 | 33,870 |
| 2025-09-30 23:41 | 2025-09-26 | CRNX | Crinetics Pharmaceuticals, Inc. | Fust Matthew K | Director | OPT+S | $44.75 | 16,000 | $716,000 | 22,836 |
| 2025-09-30 23:24 | 2025-09-29 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Khattar Jack A. | Director, Officer | OPT+S | $48.02 | 10,235 | $491,485 | 1,144,336 |
| 2025-09-30 23:07 | 2025-09-26 | PGEN | PRECIGEN, INC. | Shah Rutul R | Officer | BUY | $3.40 | 2,000 | $6,800 | 405,959 |
| 2025-09-30 23:04 | 2025-09-29 | PGEN | PRECIGEN, INC. | Tennant Phil | Officer | BUY | $3.58 | 6,000 | $21,480 | 65,031 |
| 2025-09-30 23:59 | 2025-09-26 | MBX | MBX Biosciences, Inc. | Heron Patrick J | Director, 10% owner | BUY | $18.00 | 666,666 | $11,999,988 | 5,219,440 |
| 2025-09-30 23:35 | 2025-09-26 | PEPG | PepGen Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $3.20 | 9,375,000 | $30,000,000 | 18,554,273 |
| 2025-10-01 02:15 | 2025-09-26 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | SELL | $2.31 | 79,628 | $184,156 | 31,626 |
| 2025-10-01 00:44 | 2025-09-30 | PGEN | PRECIGEN, INC. | KIRK RANDAL J | Director, 10% owner | SELL | $3.41 | 1,809,667 | $6,170,964 | 14,597,161 |
| 2025-09-30 23:33 | 2025-09-30 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | SELL | $55.08 | 6,695 | $368,761 | 16,535 |
| 2025-09-29 23:15 | 2025-09-25 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% owner | SELL | $8.02 | 500,000 | $4,008,500 | 13,863,975 |
| 2025-09-30 03:06 | 2025-09-25 | BYSI | BeyondSpring Inc. | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% owner | SELL | $1.69 | 1,800 | $3,045 | 1,845,761 |
| 2025-09-30 02:30 | 2025-09-29 | KURA | Kura Oncology, Inc. | Powl Brian T. | Officer | SELL | $8.94 | 8,891 | $79,505 | 99,676 |
| 2025-09-30 02:30 | 2025-09-29 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | Officer | SELL | $8.94 | 8,805 | $78,736 | 148,043 |
| 2025-09-30 02:30 | 2025-09-29 | KURA | Kura Oncology, Inc. | FORD KATHLEEN | Officer | SELL | $8.94 | 6,892 | $61,630 | 63,375 |
| 2025-09-30 02:30 | 2025-09-29 | KURA | Kura Oncology, Inc. | Leoni Mollie | Officer | SELL | $8.94 | 12,314 | $110,114 | 158,439 |
| 2025-09-30 02:30 | 2025-09-29 | KURA | Kura Oncology, Inc. | WILSON TROY EDWARD | Director, Officer | SELL | $8.94 | 36,615 | $327,419 | 246,853 |
| 2025-09-30 02:30 | 2025-09-29 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | Officer | SELL | $8.94 | 4,541 | $40,607 | 109,829 |
| 2025-09-29 23:26 | 2025-09-26 | AQST | Aquestive Therapeutics Inc. | Barber Daniel | Director, Officer | SELL | $6.03 | 91,343 | $551,191 | 923,430 |
| 2025-09-29 23:26 | 2025-09-26 | AQST | Aquestive Therapeutics Inc. | Boyd Peter E. | Officer | SELL | $6.30 | 10,000 | $63,000 | 278,323 |
| 2025-09-29 14:41 | 2025-09-25 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $429.58 | 8,000 | $3,436,630 | 130 |
| 2025-09-27 02:37 | 2025-09-24 | QURE | uniQure N.V. | KLEMT CHRISTIAN | Officer | OPT+S | $52.51 | 18,000 | $945,121 | 217,730 |
| 2025-09-27 02:43 | 2025-09-24 | QURE | uniQure N.V. | Kapusta Matthew C | Director, Officer | OPT+S | $41.46 | 226,316 | $9,382,473 | 651,454 |
| 2025-09-27 03:35 | 2025-09-24 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $14.06 | 9,371 | $131,780 | 203,933 |
| 2025-09-27 03:36 | 2025-09-24 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $14.05 | 12,400 | $174,175 | 18,933 |
| 2025-09-27 00:01 | 2025-09-25 | PGEN | PRECIGEN, INC. | Thomasian Harry Jr. | Officer | BUY | $3.57 | 11,216 | $40,015 | 468,626 |
| 2025-09-26 22:53 | 2025-09-24 | MNPR | Monopar Therapeutics | Tactic Pharma LLC | 10% owner | SELL | $63.61 | 550,229 | $34,999,957 | 272,026 |
| 2025-09-26 02:49 | 2025-09-23 | SMNR | Semnur Pharmaceuticals, Inc. | Scilex Holding Co | 10% owner | SELL | $16.00 | 12,500,000 | $200,000,000 | 500,000 |
| 2025-09-26 02:42 | 2025-09-23 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.03 | 2,800 | $56,084 | 919,092 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.